Perfil
Jan Beck is currently the Director at Life Science Washington and a Member at the Association of Washington Business.
He is also the Chief Operating Officer at Mozart Therapeutics, Inc. starting from 2022.
Previously, he worked as the Head-Research & Development Operations at Lyell Immunopharma, Inc.
Cargos activos de Jan Beck
Empresas | Cargo | Inicio |
---|---|---|
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Director de Operaciones | 21/03/2022 |
Life Science Washington | Director/Miembro de la Junta | - |
Association of Washington Business | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Jan Beck.
Empresas | Cargo | Fin |
---|---|---|
LYELL IMMUNOPHARMA, INC. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
LYELL IMMUNOPHARMA, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Health Technology |
Life Science Washington | |
Association of Washington Business |
- Bolsa de valores
- Insiders
- Jan Beck